Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Liraglutide significantly reduced cardiovascular events and mortality in type 2 diabetes patients with chronic kidney disease. The benefits were more pronounced in patients with lower estimated glomerular filtration rates.
Area Of Science
- Cardiology
- Nephrology
- Endocrinology
Background
- The LEADER trial showed liraglutide's cardiovascular benefits in type 2 diabetes mellitus (T2DM) patients.
- The impact of liraglutide on cardiovascular events and mortality in T2DM patients with chronic kidney disease (CKD) remained unclear.
Purpose Of The Study
- To analyze the post hoc treatment effects of liraglutide in T2DM patients with and without CKD.
- To assess liraglutide's efficacy on cardiovascular outcomes stratified by kidney function.
Main Methods
- Post hoc analysis of the LEADER trial data.
- Patients stratified by baseline estimated glomerular filtration rate (eGFR <60 vs. ≥60 mL/min/1.73 m²).
- Cox regression analysis for primary composite cardiovascular outcome, all-cause mortality, and individual components.
Main Results
- Liraglutide significantly reduced the primary composite cardiovascular outcome in patients with eGFR <60 mL/min/1.73 m² (HR, 0.69) compared to those with eGFR ≥60 mL/min/1.73 m² (HR, 0.94).
- Greater risk reductions observed for nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, and all-cause mortality in the lower eGFR group.
- No significant interaction was found when stratifying by baseline albuminuria.
Conclusions
- Liraglutide, when added to standard care, reduces the risk of major cardiovascular events and all-cause mortality in T2DM patients with CKD.
- The observed benefits of liraglutide extend across the spectrum of chronic kidney disease evaluated in the study.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
The placebo effect is commonly described in terms of testing the effectiveness of a new medication. Imagine that you work in a pharmaceutical company, and you think you have a new drug that is effective in treating depression. To demonstrate that your medication is effective, you run...
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...